These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 10506642)

  • 1. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.
    Prasad V; Massey PR; Fojo T
    J Clin Oncol; 2014 May; 32(15):1620-9. PubMed ID: 24711558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical endpoints in trials of drugs for cancer: time for a rethink?
    Koopmans PP
    BMJ; 2002 Jun; 324(7350):1389-91. PubMed ID: 12052814
    [No Abstract]   [Full Text] [Related]  

  • 3. How current assay approval policies are leading to unintended imprecision medicine.
    Salgado R; Bellizzi AM; Rimm D; Bartlett JMS; Nielsen T; Holger M; Laenkholm AV; Quinn C; Cserni G; Cunha IW; Alvarado-Cabrero I; Cree I
    Lancet Oncol; 2020 Nov; 21(11):1399-1401. PubMed ID: 33098760
    [No Abstract]   [Full Text] [Related]  

  • 4. An Open Access Database of Licensed Cancer Drugs.
    Pantziarka P; Capistrano I R; De Potter A; Vandeborne L; Bouche G
    Front Pharmacol; 2021; 12():627574. PubMed ID: 33776770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.
    Alfarouk KO; Stock CM; Taylor S; Walsh M; Muddathir AK; Verduzco D; Bashir AH; Mohammed OY; Elhassan GO; Harguindey S; Reshkin SJ; Ibrahim ME; Rauch C
    Cancer Cell Int; 2015; 15():71. PubMed ID: 26180516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
    Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
    PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials and the new good clinical practice guideline in Japan. An economic perspective.
    Ono S; Kodama Y
    Pharmacoeconomics; 2000 Aug; 18(2):125-41. PubMed ID: 11067647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of oral anticancer drugs in Japan.
    Fujiwara Y
    J Clin Oncol; 1999 Oct; 17(10):3362-5. PubMed ID: 10506642
    [No Abstract]   [Full Text] [Related]  

  • 9. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
    Forster MD; Saijo N; Seymour L; Calvert H
    Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
    Prowell T
    Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current status and problems in clinical trial for new anticancer drug in Japan].
    Fukuoka M
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):141-5. PubMed ID: 8611040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japan works to shorten "drug lag," boost trials of new drugs.
    Sinha G
    J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.